Court revives more than 500 lawsuits over Fosamax femur fracture risk
By Brendan Pierson
Sept 20 (Reuters) -A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co MRK.N failed to warn that its osteoporosis drug Fosamax increased the risk of thigh bone fractures.
A unanimous panel of the Philadelphia-based 3rd U.S. Circuit Court of Appeals ruled that federal law did not block the plaintiffs' state law claims over the drug. Fosamax was acquired in 2021 by Organon OGN.N, which agreed to indemnify Merck against liability from the lawsuits.
"We're pleased by the Third Circuit's very careful and nuanced judgment, which gives Fosamax victims an opportunity to seek justice from Merck," David Frederick of Kellogg Hansen Todd Figel & Frederick, a lawyer for the plaintiffs, said in an email.
Merck referred a request for comment to Organon, which said it "remains confident in the efficacy and safety profile of Fosamax."
About 3,115 lawsuits over Fosamax were pending against Merck in both federal and state courts around the country as of June 30, according to Organon's most recent quarterly report. The cases affected by Friday's ruling are federal cases that have been centralized in New Jersey.
The federal litigation stretches back to 2008, and has now been dismissed and revived twice. All of those decisions have hinged on the issue of federal preemption - whether the federal law governing what pharmaceutical companies are required to put on drug labels overrides, or preempts, state law claims that the label fails to warn consumers.
Merck has argued that it does, saying that in 2009 it proposed adding a warning about femur fractures but was initially rejected by the FDA. The warning was eventually added in 2011.
Now-deceased U.S. District Judge Joel Pisano in Trenton, New Jersey, ruled in Merck's favor on the preemption issue in 2013, but the 3rd Circuit overturned that ruling in 2017, concluding that issue should have been decided by a jury.
The U.S. Supreme Court in 2019 ordered the issue reconsidered once again, saying it was a legal issue for a judge, not a jury.
In 2022, U.S. District Judge Freda Wolfson, who had taken over the case, again sided with Merck on preemption.
The 3rd Circuit on Friday, however, again reversed. It said that, even though the FDA had not approved the specific warning proposed by Merck in 2009, it would not necessarily have rejected any warning about femur fractures.
It said that Wolfson's decision failed to interpret the FDA's action "in a manner that disfavors pre-emption and carries out Congress's intent to permit displacement of state law only when it is abundantly clear that it is impossible for a manufacturer to comply with both federal and state law."
Circuit Judge Kent Jordan wrote the opinion, joined by Circuit Judges Peter Phipps and Arianna Freeman.
Wolfson has since retired, and the case is now assigned in the trial court to U.S. District Judge Karen Williams. The litigation will return to that court for potential future trials.
The case is In re Fosamax (alendronate sodium) Products Liability Litigation, 3rd U.S. Circuit Court of Appeals, No. 22-3412.
For plaintiffs: David Frederick of Kellogg Hansen Todd Figel & Frederick
For Merck: Yaakov Roth of Jones Day
Read more:
Merck defeats 500 lawsuits over Fosamax bone-fracture risk warnings
Supreme Court gives Merck another shot to avoid Fosamax lawsuits
(Reporting By Brendan Pierson in New York)
</body></html>Berita Terbaru
Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.
Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.
Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.
